XALIA LEA- Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Adverse reactions
- Acronyms XALIA LEA
- Sponsors Bayer
- 12 Dec 2017 Results of pooled analysis of the XALIA and XALIA-LEA studies assessing tolerability and efficacy of rivaroxaban in patients with acute venous thromboembolism, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 16 Feb 2017 Status changed from active, no longer recruiting to completed.
- 05 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.